These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33618009)

  • 1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
    Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
    Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
    Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
    Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.
    Xu L; Su Z; Xie B
    J Clin Lab Anal; 2021 Sep; 35(9):e23912. PubMed ID: 34296781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.
    Yang H; Chen H; Zhang G; Li H; Ni R; Yu Y; Zhang Y; Wu Y; Liu H
    BMC Cancer; 2022 Apr; 22(1):382. PubMed ID: 35397524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
    Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
    Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal cut-off values for CYFRA 21-1 expression in NSCLC patients depend on the presence of benign pulmonary diseases.
    Xu RH; Liao CZ; Luo Y; Xu WL; Li K; Chen JX; Huang YF; Chen YC; Zhu L; Yuan WB
    Clin Chim Acta; 2015 Feb; 440():188-92. PubMed ID: 25304744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
    Ni J; Guo Z; Zhang L
    Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.
    Sertić Milić H; Franjević A; Bubanović G; Marušić A; Nikolić I; Puljić I
    Wien Klin Wochenschr; 2015 Jun; 127(11-12):465-71. PubMed ID: 25917364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in the lung cancer diagnosis: a clinical perspective.
    Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
    Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the discriminative methods for diagnosis of benign and malignant solitary pulmonary nodules based on serum markers.
    Wang W; Liu M; Wang J; Tian R; Dong J; Liu Q; Zhao X; Wang Y
    Oncol Res Treat; 2014; 37(12):740-6. PubMed ID: 25531720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
    Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
    Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
    Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
    Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
    Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.